Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX®) in hemodialysis patients

This publication has 17 references indexed in Scilit:

• Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis
  New England Journal of Medicine, 2002
• Methicillin-ResistantStaphylococcus aureusin the Community: A Hospital-Based Study
  Infection Control & Hospital Epidemiology, 1999
• Nosocomial infections in medical intensive care units in the United States
  Critical Care Medicine, 1999
• The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
  Emerging Infectious Diseases, 1999
• Analysis of 281,797 Consecutive Blood Cultures Performed over an Eight-Year Period: Trends in Microorganisms Isolated and the Value of Anaerobic Culture of Blood
  Clinical Infectious Diseases, 1997
• Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
  Archives of internal medicine (1960), 1995
• Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants
  JAMA, 1994
• Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus
  Diagnostic Microbiology and Infectious Disease, 1984
• Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future
  Immunochemistry, 1978
• SPECULATIONS ON THE IMMUNOLOGY OF STAPHYLOCOCCAL INFECTIONS*
  Annals of the New York Academy of Sciences, 1965